Facebook
Twitter
LinkedIn
ForwardAppropriate Use of Immune Therapy to Treat Head and Neck Cancer
While the introduction of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit.
The goal of this activity is to provide oncology healthcare providers with current and relevant clinical information in the management of patients with advanced head and neck carcinoma.
Target Audience
This activity is designed for oncology healthcare providers (oncologists, oncology nurses, nurse practitioners, and oncology physician assistants) who care for patients with head and neck cancers. No prerequisites required.
Learning Objectives
After participating in this activity, the participant will demonstrate the ability to:
- After participating in this activity, the participant will demonstrate the ability to:
- SUMMARIZE the workup of patients with head and neck squamous cell carcinoma (HNSCC).
- DISCUSS the use of molecular and histologic tumor testing and prior treatment history in selecting a treatment strategy.
- DESCRIBE emerging immunotherapy agents for the treatment of recurrent or metastatic HNSCC.
Chair and Planner
David S. Ettinger, MD
Alex Grass Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Young Jun Kim, MD, PhD
Associate Professor of Otolaryngology – Head and Neck Surgery
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Bloomberg-Kimmel Institute of Cancer Immunotherapy
Baltimore, Maryland
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Available Credit
- 0.50 ANCC